Takeda Pharmaceutical Company Limited American Depositary Receipt (TAK)
Japan's Takeda returns to Q2 profit as drugmaker recovers from impairments
Japan's Takeda Pharmaceutical returned to profitability in the second quarter following large impairment losses a year earlier and is restructuring to cut costs.
Takeda Pharmaceuticals: An Interesting Option For Income Investors
Takeda Pharmaceuticals (NYSE: TAK) offers a strong cash position and above-average dividend yield, making it an attractive option for income investors seeking international pharma exposure. The company's price/book value of 0.92 suggests it may be undervalued, presenting a potential long-term investment opportunity at a modest price. Risks include foreign currency exchange rate fluctuations and global pressure to reduce drug prices, which could impact profitability and margins.
TAK or CTLT: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Catalent (CTLT). But which of these two stocks is more attractive to value investors?
Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
TAK vs. STVN: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Stevanato Group (STVN). But which of these two stocks is more attractive to value investors?
Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
US allows increased production of Takeda's ADHD drug to address shortage
The U.S. Drug Enforcement Administration (DEA) has increased the production limit for Takeda Pharmaceutical's ADHD drug Vyvanse and its generic versions by about 24% to address the medicine's ongoing shortage in the United States.
Why Is Japanese Drugmaker Takeda Pharmaceutical Stock Trading Higher On Wednesday?
Takeda Pharmaceutical Co Ltd TAK stock is trading higher on Wednesday. Earlier today, the European Commission approved Takeda's Adzynma (recombinant ADAMTS13) for treating ADAMTS13 deficiency in children and adult patients with congenital thrombotic thrombocytopenic purpura (cTTP).
Takeda Pharmaceutical Company Limited (TAK) Q1 2025 Earnings Call Transcript
Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q1 2025 Results Conference Call July 31, 2024 6:30 AM ET Company Participants Christopher O'Reilly - Head-Investor Relations Christophe Weber - President and Chief Executive Officer Milano Furuta - Chief Financial Officer Andy Plump - President of R&D Julie Kim - President of U.S. Business Unit Conference Call Participants Hiroyuki Matsubara - Nomura Securities Steve Barker - Jefferies Shinichiro Muraoka - Morgan Stanley Mike Nedelcovych - Cowen Seiji Wakao - JPMorgan Chase & Co Tony Ren - Macquarie Kasumi Haruta - UBS Investment Bank Hidemaru Yamaguchi - Citigroup Miki Sogi Sanford - Bernstein Christopher O'Reilly Thank you very much for taking time out of your very busy schedule to join us for this first quarter earnings call by Takeda for FY ‘24. I'm the master of ceremony today.
Takeda's AI-Powered Strategy To Optimize Operations And Accelerate Its Pipeline
Takeda Pharmaceutical Company Limited showed signs of improvement despite revenue declines in oncology and neurosciences, thanks to gains in gastrointestinal and inflammation sectors and strategic leadership changes. The company's “returning to growth program” aims to increase operating margins by 100-250 basis points annually from 2025 onwards. Despite a challenging FY2023 with a significant net profit decline, Takeda expects its AI-powered returning to growth program to improve financial stability and shareholder returns by 2025.
Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India
Japan's Takeda Pharmaceutical gave India's Sun Pharmaceutical and Cipla the rights to commercialize gastrointestinal drug Vonoprazan in the country.
What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?
Monday, Takeda Pharmaceutical Co Ltd TAK announced topline data from its SKYLINE and SKYWAY Phase 3 studies of Soticlestat (TAK-935) for the treatment of Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS).
